Novartis bets $3B on unproven breast cancer therapy SNV4818

Novartis has struck a deal to buy experimental breast cancer therapy SNV4818 from Synnovation Therapeutics. The acquisition could reach a total value of $3 billion, with the transaction expected to close in early 2026. The move strengthens Novartis's focus on cancer treatments while divesting Synnovation of its key asset.

The therapy, SNV4818, is a selective PI3Kα inhibitor designed for patients with HR+/HER2- breast cancer. It specifically targets a mutated form of the PI3Kα protein, which may reduce side effects seen in current treatments. Early lab studies have shown promising tumor-shrinking activity, though the compound remains in preliminary testing.

The deal includes an upfront payment of $2 billion, with an additional $1 billion tied to future milestones. Despite the high valuation, no clinical trials for SNV4818 appear on public databases like ClinicalTrials.gov as of March 2026. Novartis's decision reflects its broader strategy to expand its oncology pipeline. Following the announcement, Novartis shares dipped by 0.94%, suggesting mixed investor reaction to the acquisition's cost and potential risks.

The acquisition positions Novartis to advance SNV4818 through further development, pending successful clinical results. If approved, the therapy could offer a more targeted option for certain breast cancer patients. The deal's completion in 2026 will mark a significant shift for Synnovation, which is now exiting its lead programme.